IRS1 and diabetes mellitus: Moreover, r-A-FABP treatment impaired the insulin-mediated eNOS pathway in vascular endothelial cells by inhibiting insulin receptor substrate 1 (IRS1) and Akt activation [100], which implicates the mechanistic linkage between circulating A-FABP and endothelial cell dysfunction in diabetes.